Financial PerformanceBTSG raised its FY24 guidance ranges, highlighting expectations for strong top line growth driven by new drug introductions and continued strength in oncology.
Growth PotentialBTSG remains committed to reducing leverage to approximately 3.0x over time while maintaining strong growth in specialty and home health segments, supported by significant institutional pharmacy Rx growth.
Strategic InvestmentsKKR has entered into an agreement to purchase approximately 12 million shares of BTSG common from WBA in a private transaction, indicating confidence in BTSG's future prospects.